Patent · US Active

Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes

US11773154B2 · kind B2 · utility

0Cited by
2References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2018
Grant dateOct 3, 2023
Priority date—
Expiry dateAug 18, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N15/746
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.